Cabotegravir

DRUG4 trials

Sponsors

Centre for the AIDS Programme of Research in South Africa, ViiV Healthcare, Gilead Sciences

Conditions

HIV InfectionsHuman Immunodeficiency VirusInfection, Human Immunodeficiency Virus

Phase 1

Effect of Rifabutin on the Pharmacokinetics of Oral Cabotegravir in Healthy Subjects

CompletedNCT03149848

ViiV HealthcareHIV Infections, Infection, Human Immunodeficiency Virus

Start: 2017-06-06End: 2017-09-07Updated: 2020-09-17

Phase 2

Safety and Acceptability of Cabotegravir in HIV Uninfected Women in KwaZulu-Natal, South Africa

WithdrawnNCT02462772

Centre for the AIDS Programme of Research in South AfricaHuman Immunodeficiency Virus

Start: 2015-10-31End: 2018-09-30Updated: 2015-11-05

A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)

Active, not recruitingNCT05996471

ViiV HealthcareHIV Infections

Start: 2023-08-17End: 2028-11-09Updated: 2026-03-11

Phase 3

Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy

Not yet recruitingNCT07682961

Gilead SciencesHIV Infections

Start: 2026-07-01End: 2033-03-01Target: 590Updated: 2026-07-06

Related Papers

Evaluation of the effect of UGT1A1 polymorphisms on the pharmacokinetics of oral and long-acting injectable cabotegravir

Journal of Antimicrobial Chemotherapy2020-03-2711 citations